(Q39270204)

10 September 2017

title

Delivery of interferons and siRNA targeting STAT3 using lentiviral vectors suppresses the growth of murine melanoma (English)

1 reference

10 September 2017

X Wang

1

1 reference

10 September 2017

P Liu

2

1 reference

10 September 2017

H Liu

3

1 reference

10 September 2017

W Yang

4

1 reference

10 September 2017

Z Liu

5

1 reference

10 September 2017

Z Zhuo

6

1 reference

10 September 2017

Y Gao

7

1 reference

10 September 2017

publication date

28 September 2012

1 reference

10 September 2017

1 reference

10 September 2017

volume

19

1 reference

10 September 2017

issue

12

1 reference

10 September 2017

page(s)

822-827

1 reference

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Raising the bar: the curative potential of human cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

A critical function for type I interferons in cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Gamma delta T cells provide an early source of interferon gamma in tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Interferons, immunity and cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Interferon: current status and future prospects in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Lentiviral vectors in gene therapy: their current status and future potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Cancer immunotherapy: the interferon-alpha experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Combinational therapy of interferon-α and chemotherapy normalizes tumor vasculature by regulating pericytes including the novel marker RGS5 in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Interferon-γ links ultraviolet radiation to melanomagenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.65

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CGT.2012.65

1 reference

10 September 2017

1 reference